Neuroscience Collaboration with AstraZeneca
AstraZeneca and Tufts University’s School of Medicine and Sackler School of Graduate Biomedical Sciences are collaborating as part of a three year agreement to perform cutting-edge research into biological targets in the field of neuroscience. As part of the agreement AstraZeneca is working with Tufts to establish a team of postdoctoral researchers that will explore a variety of neurological pathways implicated in brain disease. Stephen Moss, Ph.D., professor of neuroscience at Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences, will serve as principal investigator and oversee the research. The group’s work is part of the AstraZeneca Neuroscience Innovative Medicines Unit, which is a small team that advances neuroscience discovery research exclusively via external partners.